What type of medicine is larotrectinib?

Larotrectinibis an inhibitor of tropomyosin receptor kinaseTRKA, TRKB and TRKC, 2018< In November 2020, the U.S. Food and Drug Administration (FDA) approved larotrectinib, an oral treatment for adults and children with neurotrophic receptor tyrosine kinase (NTRK) gene fusion solid tumors. Larotrectinib is the first TRK inhibitor targeting cancers expressing this mutation.

Patients receiving larotrectinib have experienced central nervous system (CNS) adverse reactions, including dizziness, cognitive impairment, mood disorders, and sleep disturbances. Among patients treated with larotrectinib, 42% developed various central nervous system symptoms including cognitive impairment, mood disorders, dizziness and sleep disorders, and 3.9% experienced grade 3-4 symptoms. 11% of patients developed cognitive impairment. The median time to onset of cognitive impairment was 5.6 months (range: 2 days to 41 months). Occurs in≥ Cognitive impairments in 1%of patients include memory impairment (3.6%), confusion (2.9%), attention disorder (2.9%), delirium Delirium (2.2%), cognitive impairment (1.4%), and 2.5% of patients experienced grade 3 cognitive adverse reactions. Among 30patients with cognitive impairment, 7%required dose adjustments and 20%required dose interruptions. 14% of patients developed mood disorders. The median time to onset of mood disorders was3.9months (range: 1 days to 40.5 months). Occurs in≥ Mood disorders reported in 1%of patients included anxiety (5%), depression (3.9%), agitation (2.9%) and irritability (2.9%). 0.4%of patients developed Grade 3 mood disorders. 27% of patients experienced dizziness, and 1.1% of patients experienced Grade 3 dizziness. Of the 74 patients who experienced dizziness, 5% required a dose adjustment and 5% required a dose interruption. 10% of patients develop sleep disorders. Sleep disorders included insomnia (7%), hypersomnia (2.5%), and sleep disturbance (0.4%). There is no grade 3-4 sleep disorder. Of 28patients who experienced sleep disturbance, 1 each (3.6%) required dose modification or dose interruption. Inform patients and caregiversof these risks of larotrectinib. Advise patients not to drive or operate dangerous machinery when experiencing neurological adverse reactions. Withhold or permanently discontinue larotrectinib based on severity. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.